搜索优化
English
搜索
图片
Copilot
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
6 天
恒瑞医药(600276.SH):新药临床试验获批,加速布局抗肿瘤领域
注射用SHR-9839则是恒瑞医药自主研发的人源化抗体药物,拟用于治疗晚期恶性肿瘤,通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。目前全球已有1款同靶点药物获批上市。截至目前,SHR-9839相关项目累计已投入研发费用约5,745万元。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Prince Harry settles suit
Los Angeles wildfire updates
California fires: How to help
Released from prison
Coast Guard chief fired
Turns down plea deal
Files $500M defamation suit
Silk Road founder pardoned
Meta ex-COO sanctioned
Raising prices again
1st Japanese elected to HOF
Faces new allegations
Soda button reinstalled
Birthright citizenship suit
Trailblazing cartoonist dies
The Band's keyboardist dies
Voice of Navy football dies
Discuss strengthening ties
FDA approves nasal spray
Murder charge upheld
Can target schools, churches
SCOTUS grants new hearing
Wildfires near San Diego
Bryan pastor found guilty
Israel’s top general resigns
Elise Stefanik testifies
Former prosecutor faces trial
Judge blocks report release
反馈